Advertisement

From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection”

  • Ena Wang
  • Francesco M. Marincola
Chapter

Abstract

This book collects salient observational data, derived predominantly from human studies, regarding the mechanism(s) of rejection in various pathologic conditions; the premise is that immune rejection, better defined as “immune-mediated, tissue-specific destruction” (TSD) (Wang et al. 2008), comprises a broad range of ­phenomena ranging from tumor regression, to clearance of pathogen through destruction of infected cells, autoimmunity, allograft rejection by the host and host vs. graft reactions. Like different hands can turn on or off a switch, distinct ­mechanisms can trigger TSD, however, a convergent pathway is ultimately observed when TSD occurs consisting of a dramatic switch from chronic to acute inflammation (Mantovani et al. 2008).

Keywords

Chronic Obstructive Pulmonary Disease Interferon Regulatory Factor Allograft Rejection Acute Allograft Rejection Acute Inflammatory Process 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Asselah T, Bieche I, Narguet S et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57(4):516–524.PubMedCrossRefGoogle Scholar
  2. Benencia F, Courreges MC, Conejo-Garcia JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12(5):789–802.PubMedCrossRefGoogle Scholar
  3. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75(15):7059–7066.PubMedCrossRefGoogle Scholar
  4. Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69(6):2685–2693.PubMedCrossRefGoogle Scholar
  5. Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008; 133(1):26–33.PubMedCrossRefGoogle Scholar
  6. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27):4410–4417.PubMedCrossRefGoogle Scholar
  7. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46(5):1548–1563.PubMedCrossRefGoogle Scholar
  8. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960–1964.PubMedCrossRefGoogle Scholar
  9. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67(5):1883–1886.PubMedCrossRefGoogle Scholar
  10. Hardstedt M, Finnegan CP, Kirchhof N et al. Post-transplant upregulation of chemokine messenger RNA in non-human primate recipients of intraportal pig islet xenografts. Xenotransplantation 2005; 12(4):293–302.PubMedCrossRefGoogle Scholar
  11. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69(7):3077–3085.PubMedCrossRefGoogle Scholar
  12. He XS, Ji X, Hale MB et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006; 44(2):352–359.PubMedCrossRefGoogle Scholar
  13. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6(9):644–658.PubMedCrossRefGoogle Scholar
  14. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25(3):349–360.PubMedCrossRefGoogle Scholar
  15. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113(15):3620–3630.PubMedCrossRefGoogle Scholar
  16. Jin P, Wang E, Provenzano M, Stroncek D, Marincola FM. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 2007; 27(5):437–448.PubMedCrossRefGoogle Scholar
  17. Karason K, Jernas M, Hagg DA, Svensson PA. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc Disord 2006; 6:29.PubMedCrossRefGoogle Scholar
  18. Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta 2008; 1783(9):1654–1662.PubMedCrossRefGoogle Scholar
  19. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2008; 371(9614):771–783.PubMedCrossRefGoogle Scholar
  20. Nanda S, Havert MB, Calderon GM et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008; 3(10):e3442.PubMedCrossRefGoogle Scholar
  21. Okamoto Y, Folco EJ, Minami M et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008; 102(2):218–225.PubMedCrossRefGoogle Scholar
  22. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654–2666.PubMedCrossRefGoogle Scholar
  23. Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3(7):RESEARCH0035.Google Scholar
  24. Panelli MC, Stashower M, Slade HB et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2006; 8(1):R8.CrossRefGoogle Scholar
  25. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007; 89(6–7):744–753.PubMedCrossRefGoogle Scholar
  26. Reeve J, Einecke G, Mengel M et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9(8):1802–1810.PubMedCrossRefGoogle Scholar
  27. Saint-Mezard P, Berthier CC, Zhang H et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22(3):293–302.PubMedCrossRefGoogle Scholar
  28. Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 1969; 164(2):365–380.PubMedCrossRefGoogle Scholar
  29. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349(2):125–138.PubMedCrossRefGoogle Scholar
  30. Shanker A, Verdeil G, Buferne M et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007; 179(10):6651–6662.PubMedGoogle Scholar
  31. Taniguchi T. Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol 1997; 173(2):128–130.PubMedCrossRefGoogle Scholar
  32. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. Irf family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19:623–655.PubMedCrossRefGoogle Scholar
  33. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581–3586.PubMedGoogle Scholar
  34. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29(6):256–262.PubMedCrossRefGoogle Scholar
  35. Worschech A, Chen N, Yu YA et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. BMC Genomics 2009; 10:301.PubMedCrossRefGoogle Scholar
  36. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169(3):1556–1560.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI)National Institutes of HealthBethesdaUSA

Personalised recommendations